Ehlers–Danlos syndrome: how to diagnose and when to perform genetic tests

Glenda Sobey

ABSTRACT

The term Ehlers–Danlos syndrome (EDS) encompasses a group of inherited connective tissue disorders. The manifestations of EDS can be seen in skin, joints, blood vessels and internal organs and vary from mild to severe and life threatening. Each subtype is a separate and different condition. The genetic basis of many subtypes has now been elucidated, confirming heterogeneity. An awareness of the different conditions within this group is the starting point towards accurate diagnosis. Accurate elicitation of history and clinical signs is vital in selecting the correct confirmatory investigation. Skin biopsy with electron microscopy can be helpful in the decision process of whether and when to perform genetic testing. Correct diagnosis within the EDSs allows targeted management, family screening and prenatal diagnosis.

INTRODUCTION

Ehlers–Danlos syndrome (EDS) is composed of separate and distinct entities. The underlying genetic defect, where known, is different in each subtype. Many of the clinical features are commonly seen between subtypes where skin, joints, blood vessels and internal organs are variably affected. Accurate clinical diagnosis with appropriate choice of genetic test can thus be challenging.

The correct diagnosis of EDS is further vexed by an outdated classification, confounding symptomatology and inaccuracy in eliciting clinical signs as these can be subtle. Furthermore, several types are rare and will be seen seldom or never in a physician’s practice. Many types of EDS present in childhood. The presentation of vascular EDS as sudden death in adulthood is, however, well described as is the detection of affected but asymptomatic individuals picked up on cascade screening. Throughout life, there are some presenting features that should alert the physician to a possible EDS diagnosis (box 1).

A systematic approach to the patient with suspected EDS is essential to avoid costly and unnecessary investigations, but first one needs to be aware of the different subtypes within this group and their diagnostic features.

CLASSIFICATION

Table 1 shows the Villefranche Classification of EDS together with subsequently identified subtypes and the molecular classification.

Identification of genetic changes affecting the synthesis and structure of type I, III and V collagen prompted the Villefranche Classification. This classification is still widely used. The previous classification of EDS using numbers, for example, EDS IV for vascular EDS, EDS I for classical EDS has been discarded as this was purely on clinical grounds.

The molecular genetic elucidation of further subtypes means that a new classification is required.

Among the subtypes mentioned in table 1, the classical, vascular and hypermobile types are most commonly seen. The other types mentioned are extremely rare.

HISTORY

The personal and family history are potentially contributory, and it is useful for a detailed pedigree to be completed. It is important not to miss other diagnoses that are sometimes confused with EDS and have their own specific treatment (box 2).

EXAMINATION

Clinical examination should include examination of the whole skin and assessment of the joints for hypermobility. The Beighton score (table 2) is the standard for recording this, and a score of 5 or more indicates a generalised joint hypermobility.

SPECIAL INVESTIGATIONS

Skin biopsy is helpful in patients where particular subtypes are considered.

Skin biopsies can be taken for histology, electron microscopy and fibroblast culture. For patients who have had vascular events, do be aware that they may be on anticoagulants and respond according to surgical guidelines.

CLASSICAL EDS

Marked skin hyperextensibility (figure 1), together with widened atrophic cutaneous scars (figure 2) and generalised joint hypermobility, is typical of classical EDS (MIM 130010). Additional skin signs are easy bruising with staining due to haemosiderin deposition (particularly noticeable on the shins and dorsa of the hands), subcutaneous spheroids (fat lobules that have calcified after losing their blood

---

References and further details are available in the full publication.
are termed ‘type V collagen have long been known to cause classical EDS.5 The COL5A1 and COL5A2 genes are implicated. Mutations in the next step is molecular genetic testing of type V collagen.

Reduced availability of type V collagen is thought to be the major disease causing mechanism.6 A large number of different mutations have been identified in type V collagen in patients with classical EDS. At present, there is no obvious genotype–phenotype correlation.

Classical EDS is a dominantly inherited condition. Severity is seen to vary significantly, even within the same family.

Recommendations for classical EDS management

► Cardiology assessment including echocardiogram.
► Regular cardiology follow-up.
► Joint hypermobility managed by rheumatology including physiotherapy and occupational therapy.
► Shin pads helpful to reduce injury in childhood.
► Patient should be known to local plastic surgeons for expert suturing of any wounds.
► Wear medical warning bracelet inscribed ‘classical EDS’.
► Patient to carry information leaflet on the condition to provide to school, employer, healthcare staff and other appropriate contacts.

Box 2  Conditions mistaken for Ehlers–Danlos syndrome

► Osteogenesis imperfecta
► Loeys–Dietz syndrome
► Skeletal dysplasias
► Mucopolysaccharidoses
► Cutis laxa
► Pseudoxanthoma elasticum
► Ullrich congenital muscular dystrophy
► Bethlem myopathy

VASCULAR EDS

The diagnosis of vascular EDS (MIM 130050) carries with it the life-threatening risks of blood vessel and organ rupture, sometimes in childhood. The clinical features typical of vascular EDS may be subtle or absent, making diagnosis difficult particularly where there is no positive family history. Sudden death in the third or fourth decade of life can be the presenting feature.

Features of vascular EDS

Easy bruising: This can be seen at sites not prone to trauma and is often the presenting sign in childhood. Child protection agencies may have been involved due to this prominent feature.

Skin: This is typically thin and translucent with visible underlying vessels. The skin is not hyperextensible but can be fragile (figure 5).

Facial features: In some patients, the typical features of a thin pinched nose, prominent eyes and lobeless ears together with a lack of subcutaneous fat are so striking that the diagnosis may be suspected on this aspect alone.

Acrogeria: A prematurely aged appearance particularly to the hands and feet due to thin wrinkled skin is sometimes seen.

Joint hypermobility: In vascular EDS, this is usually limited to the small joints of the hands.

Congenital talipes: May be associated.

Repeated pneumothoraces: Can be the initial presentation.

A diagnosis of vascular EDS needs to be excluded in any patient where an unexplained arterial rupture or bowel rupture has occurred.8 This is equally important where the diagnosis is not vascular EDS as a wide range of interventional procedures (which would be contraindicated and potentially lethal in vascular EDS) is then available to the patient.

The major risks for patients with vascular EDS are arterial (including aortic) dissection, rupture and aneurysm. The sigmoid colon is the commonest site for bowel rupture—this

Table 1  Ehlers–Danlos syndrome classification

<table>
<thead>
<tr>
<th>Villefranche classification</th>
<th>Inheritance pattern</th>
<th>Molecular classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Classical</td>
<td>Autosomal dominant</td>
<td>COL5A1, COL5A2</td>
</tr>
<tr>
<td>Hypermobile</td>
<td>Autosomal dominant</td>
<td>Unknown</td>
</tr>
<tr>
<td>Vascular</td>
<td>Autosomal dominant</td>
<td>COL3A1</td>
</tr>
<tr>
<td>Kyphoscoliotic</td>
<td>Autosomal recessive</td>
<td>Lysyl hydroxylase 1 (PLOD1)</td>
</tr>
<tr>
<td>Arthrochalasic</td>
<td>Autosomal dominant</td>
<td>Targeted COL1A1, COL1A2</td>
</tr>
<tr>
<td>Dermatosparactic</td>
<td>Autosomal recessive</td>
<td>Procollagen N-proteinase (ADAMTS2)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Subtype identified after Villefranche</th>
<th>Inheritance pattern</th>
<th>Molecular classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenascin-X deficient</td>
<td>Autosomal recessive</td>
<td>TNXB</td>
</tr>
<tr>
<td>Ehlers–Danlos syndrome with scoliosis, myopathy, hearing impairment</td>
<td>Autosomal recessive</td>
<td>FKBP14</td>
</tr>
<tr>
<td>Musculocontractual Ehlers–Danlos syndrome</td>
<td>Autosomal recessive</td>
<td>CHST14</td>
</tr>
</tbody>
</table>

Table 2  The Brighton score for joint hypermobility

<table>
<thead>
<tr>
<th>Joint mobility</th>
<th>Unilateral</th>
<th>Bilateral</th>
</tr>
</thead>
<tbody>
<tr>
<td>Passive dorsiflexion of fifth finger beyond 90°</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Passive flexion of thumb to forearm</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Hyperextension of the elbow beyond 10°</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Hyperextension of the knee beyond 10°</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Forward flexion of the trunk with knees fully extended and palms resting on the floor</td>
<td>Present=1</td>
<td></td>
</tr>
</tbody>
</table>

EDS, Ehlers–Danlos syndrome.
can be seen at all ages. Obstetric complications include uterine and arterial rupture as well as massive postpartum haemorrhage and severe lacerations from tearing at vaginal delivery.

Vascular EDS is caused by mutations in the COL3A1 gene that encodes type III collagen. Molecular genetic testing is highly sensitive and specific for vascular EDS. Accurate prognosis by genotype–phenotype correlation has been extensively investigated but is not yet reliable. Parental mosaicism is recognised and can explain unexpected inheritance patterns. There are also characteristic changes on electron microscopy of skin with marked collagen diameter variability (figure 6).

**Recommendations for vascular EDS medical management**

- Surgical and endovascular interventions are discouraged and conservative medical management preferred where possible.
- Wear medical warning bracelet inscribed ‘vascular EDS’ with information on specific emergency care given to the organisation supplying the bracelet.
- Regular follow-up in cardiology is advised, preferably in a specialised unit. The role of imaging and medication is still in the early stages of use and evidence is being gathered. Medication aimed at reducing the incidence of arterial rupture or dissection has been trialled.
- Need for psychological support following the diagnosis with special attention to the needs of children and adolescents requiring transitional care.

**HYPERMOBILE EDS**

There is no diagnostic test for this condition, and the genetic basis is still unknown. Add to this the fact that joint hypermobility is reasonably common (thought to be up to 10% in the general population) and that even within the same family the manifestations can vary and it is clear why accurate delineation remains elusive. There is still much debate whether hypermobile EDS (MIM 130020) and joint hypermobility syndrome represent the same condition. Joint hypermobility does appear to be dominantly inherited in many families.

The Beighton score is useful in confirming the presence and extent of joint hypermobility, although this score can often decrease with age, injury, surgery and the effects of arthritis.

Although patients in this group are not prone to life-threatening complications, the effects can be debilitating in
the extreme. The combination of severe chronic joint pain and the symptoms of autonomic dysfunction can severely impair quality of life. Gastrointestinal and urinary symptoms are also commonly reported. Women present more commonly with this condition than men—this is still unexplained.

Postural orthostatic tachycardia syndrome (POTS) is well recognised in this group. POTS is a syndrome of dysautonomia and has a wide range of symptoms that occur particularly on postural change or standing. Transient loss of consciousness, dizziness, palpitations, chest pain and shortness of breath are all recognised.

Recommendations for hypermobile EDS management

▸ Referral to rheumatology for assessment of appropriate rehabilitation by physiotherapy and occupational therapy.
▸ Following advice of physiotherapy, regular graded exercise is helpful.
▸ Consider a referral to a multidisciplinary pain clinic where chronic pain is a significant component of morbidity.
▸ Actively reassure patient that they do not have a worrying type of EDS.
▸ Put patient in touch with appropriate support group.

TENASCIN X-DEFICIENT EDS

The autosomal-recessive condition of Tenascin X-deficient EDS has features of marked skin laxity, pronounced joint hypermobility and severe bruising. The abnormal scarring seen in classical EDS is absent. Electron microscopy is sometimes helpful.

The parents (particularly mothers) of affected individuals, who have a single Tenascin X mutation themselves, can have features of joint hypermobility. There is no evidence to suggest that this is a common cause for hypermobile EDS.

KYPHOSCOLIOTIC EDS

This autosomal-recessive condition (MIM 225400) is characterised by early-onset, progressive kyphoscoliosis, hypotonia and gross motor delay as well as joint hypermobility, skin hyperextensibility, easy bruising, atrophic scarring and fragility of the sclerae with raised intraocular pressure. Vascular rupture is reported. Cognitive development is normal. Because of severe muscle hypotonia and delayed motor development, children with this condition are often thought to have a primary neuromuscular disease.

It is caused by deficiency in the enzyme lysyl hydroxylase. The diagnosis can be confirmed by showing an increased ratio of lysylpyridinoline to hydroxylysylpyridinoline crosslinks in the urine. These test results correlate fully with the presence of a homozygous or compound heterozygous mutation in the PLOD1 gene.

FKBP14 EDS

This autosomal-recessive condition (MIM 614557) should be considered in all patients thought to have kyphoscoliotic EDS, but where urine crosslinking is normal and no mutations are found in PLOD1, particularly if there is sensorineural hearing impairment. The severe generalised hypotonia at birth with marked muscle weakness usually improves in infancy.

CHST14 EDS/MUSCULOCONTRACTURAL EDS

The features of this rare condition (MIM 601776) include progressive kyphoscoliosis, adducted thumbs in infancy, clubfoot, arachnodactyly, joint hypermobility, fragile and hyperextensible skin with atrophic scars and delayed wound healing.

ARTHROCHALASIC EDS

Arthrochalasic EDS (MIM 130060) is extremely rare. Congenital bilateral hip dislocation, severe joint hypermobility with recurrent dislocations, skin hyperextensibility, easy bruising, atrophic scars, kyphoscoliosis and osteopaenia are the features of this autosomal-dominant condition. It is caused by mutations in type I collagen that lead to loss of exon 6 or part thereof.
DERMATOSPARACTIC EDS

Dermatosparactic EDS (MIM 225410) is extremely rare. This autosomal-recessive condition is caused by deficient activity of the procollagen-N-proteinase encoded by the ADAMTS2 gene. The clinical features include redundant, sagging, fragile skin, delayed closure of the fontanelles, blue sclerae, umbilical hernia and short stature. Most patients have a very severe phenotype presenting at birth, but some have milder manifestations. Electron microscopy of skin shows characteristic 'hierarchy fibrils'. The diagnosis is confirmed through genetic testing of ADAMTS2.

CONCLUSION

There are now a wide range of EDS subtypes recognised clinically, which can be confirmed by molecular genetic testing. We appreciate now that these are multisystem disorders. Clinical features are shared between some subtypes making diagnosis of these rare conditions challenging. As these conditions are individually rare, the decision when to perform genetic tests can be difficult and when the clinical diagnosis is in doubt referral to specialist centres is the most efficient way forward.

The development of next-generation sequencing platforms will hasten the molecular genetic testing process and make it more economical, but the clinician needs to be aware of EDS and its variable presentations to consider it as a potential cause. The firm diagnosis of EDS, in some forms life threatening, enables genetic counselling and targeted management to optimise both quality of life and life expectancy in this group of rare disorders.

Competing interests None.

Patient consent Obtained.

Provenance and peer review Commissioned; externally peer reviewed.

REFERENCES